Gilead Sciences (GILD): Why Splitting GILD Is A Bad Idea - Piper Jaffray
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Piper Jaffray analyst, Joshua Schimmer, reiterated his Overweight rating on shares of Gilead Sciences (NASDAQ: GILD) along with his price target of $108 while shedding light on the myth that breaking up GILD is a good idea.
The analyst believes that breaking up GILD into its HIV and HCV franchises could reduce the hyper-focus on HCV which is distracting the company from a materially undervalued and robust HIV business (that includes bictegravir/Descovy). The analyst thinks splitting up the company is a poor idea and the probability of this occurring is negligible.
Separating HIV and HCV will require replication of sales forces, commercial infrastructure, administrative efforts and virology R&D. It would also have to address tax considerations and ex-US cash.
Shares of Gilead Sciences closed at $80.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- New Oriental Education (EDU) PT Raised to $60 at Brean Capital
- Akamai (AKAM) PT Raised to $65 at Stifel
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesPiper Jaffray, Joshua Schimmer
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!